Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients, 18 - 75 years of age
Diagnosis of Psoriatic Arthritis (Moll and Wright or CASPAR criteria) of \>/= 6 months duration
Have \>/= 3 swollen and \>/= 3 tender joints
Inadequate response to a current or previous oral DMARD or NSAID therapy
Current oral DMARDs must be at stable dose for the appropriate duration (e.g. 14 days for sulfasalazine and 28 days for methotrexate or oral steroids)
NSAIDs up to maximum recommended dose are permitted if at stable dose for at least 14 days prior to first dose of study drug, but not more than one NSAID simultaneously (except for low-dose aspirin for cardioprotection)
Body mass index (BMI) 18 - 42 kg/m2 inclusive
You may not be if
Previous prolonged treatment with a biologic DMARD; use of biologic DMARD within 3 months or 5 times its elimination half-live (whichever is longer) prior to first dose of study drug
Previous use of B-cell depleting biologic DMARDs
Any previous treatment with alkylating agents such a cyclophosphamide or chlorambucil or with total lymphoid irradiation
History of or current inflammatory joint disease other than psoriatic arthritis; Gout or pseudogout that is current or has been active within the past 6 months
Positive for hepatitis B, hepatitis C or HIV infection
Any acquired or congenital immune deficiency or history of disease known to cause significant alteration in immunologic function
Acute clinically significant infection in the 6 weeks prior to administration of study drug, history or presence of chronic infection, or history of recurrent infection as an adult
